It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ObsEva SA (OBSV) CHF1

Sell:$2.92 Buy:$2.93 Change: $0.03 (1.03%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Sell:$2.92
Buy:$2.93
Change: $0.03 (1.03%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Sell:$2.92
Buy:$2.93
Change: $0.03 (1.03%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).

Contact details

Address:
Chemin des Aulx 12
PLAN-LES-OUATES
1228
Switzerland
Telephone:
+41 (22) 5521558
Website:
www.obseva.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OBSV
ISIN:
CH0346177709
Market cap:
$157.12 million
Shares in issue:
57.55 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Switzerland
Currency:
US dollar
Indices:
n/a

Key personnel

  • Brian O'Callaghan
    Chief Executive Officer
  • David Renas
    Chief Financial Officer
  • Jean-Pierre Gotteland
    Chief Scientific Officer, Head of Research & Development
  • Clive Bertram
    Chief Commercial Officer
  • Elizabeth Garner
    Chief Medical Officer
  • Wim Souverijns
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.